Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call February 11, 2026 4:30 PM EST Chad Fugure - Vice President of Investor Relations Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director Scott Smith - CFO, Executive VP &…
Pharma taking PBAC to court over knockback
PERTH-BASED Lawley Pharmaceuticals has lodged an application in the Federal Court of Australia seeking judicial review of the decision by the Pharmaceutical Benefits Advisory Committee (PBAC) in Nov 2025 to not recommend listing of AndroFeme 1, a…
Hims & Hers: Does Big Pharma Always Win? (Rating Downgrade) (NYSE:HIMS)
Hims & Hers faces heightened regulatory and legal risk after FDA escalation and Novo Nordisk litigation over compounded GLP-1s. GLP-1s account for roughly 25% of HIMS revenue; losing this segment threatens growth and has triggered a 60% stock…
SCHOTT Pharma AG & Co. KGaA (SHTPY) Q1 2026 Earnings Call Transcript
SCHOTT Pharma AG & Co. KGaA (SHTPY) Q1 2026 Earnings Call February 11, 2026 5:00 AM EST Tobias Erfurth - Head of Investor Relations Andreas Reisse - Chairman of Management Board & CEO of SCHOTT Pharma Management AG Reinhard Mayer - CFO & Member of…
Royalty Pharma targets 3%-8% royalty receipts growth in 2026 while advancing $4.7B in transactions (NASDAQ:RPRX)
Earnings Call Insights: Royalty Pharma (RPRX) Q4 2025 CEO Pablo Legorreta stated that '2025 was truly a landmark year for Royalty Pharma as we executed successfully towards our goal to be the premier capital allocator in life sciences with Seeking…
Biotechs, wary of being tied to Big Pharma, form new industry group as hedge against Trump policies
As President Trump hails pricing agreements with the pharmaceutical industry — and as major drugmakers tout their participation in the TrumpRx website — some biotech companies are worried they have been left out in the cold. Now…
Royalty Pharma Q4 Earnings Call Highlights
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks Royalty Pharma NASDAQ: RPRX executives highlighted what they described as a “landmark year” in 2025, pointing to double-digit top-line growth, continued capital deployment…
Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 7,479 Shares
Urogen Pharma (NASDAQ:URGN - Get Free Report) General Counsel Jason Drew Smith sold 7,479 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51.
Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Misses Expectations By $0.90 EPS
Royalty Pharma (NASDAQ:RPRX - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.38 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.28 by ($0.90), reports. The…
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year High - Here's What Happened
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report)'s share price hit a new 52-week high during trading on Wednesday. The company traded as high as $45.16 and last traded at $45.0650, with a volume of 1977195 shares changing hands. The stock had…
Behind Madhya Pradesh cough syrup deaths: Bad batch, compromised system, a phone call
By then, 15 children had already died in Chhindwara. The chargesheet filed by the Madhya Pradesh police reveals that the deaths of over 20 children were not the result of a single catastrophic error, but “the outcome of a continuous and…
Stock Market LIVE Updates: GIFT Nifty hints at flat start amid mixed cues; Nikkei 225 hits 58k
Stock Market LIVE Updates, Thursday, February 12, 2026: Indian equity benchmark indices, Sensex and Nifty, are likely to witness a flat start on Thursday amid mixed global cues. Around 06:45 AM, the GIFT Nifty was trading at 25,998 levels, up by…
/afaqs/media/media_files/2026/02/12/aishwarya-2026-02-12-00-05-20.png)
Aishwarya Mohanraj names Mounjaro, spotlighting GLP-1's rise
When comedian and content creator Aishwarya Mohanraj revealed in a recent YouTube video that she used Eli Lilly's Mounjaro injections for weight loss, she did something few Indian public figures have: publicly name a GLP-1 drug. The disclosure…
Carterra launches industry's first 48-channel HT-SPR platform for advanced label-free biomolecular screening and characterization
Carterra Inc., the leading provider of technologies enabling high-throughput biology, today announced the launch of the Carterra Vega High-Throughput Surface Plasmon Resonance (HT-SPR) instrument. The industry's first 48-channel SPR platform, Vega…
Nifty outlook: Index to consolidate; Ajit Mishra suggests 3 stocks to buy
Markets traded in a lackluster manner on Wednesday and ended almost unchanged, taking a breather after the recent surge. After an initial uptick, the Nifty index hovered within a narrow range for most of the session and finally closed at 25,953.85.
Receive a Daily briefing on Pharma Industry News
Get Started